Trials / Completed
CompletedNCT01856998
Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery
Therapeutic Equivalence Study of Propofol Using Target-Controlled Infusion of Propofol 2% (20 mg/mL) MCT Fresenius Compared With Diprivan® 20 mg/mL (AstraZeneca) in Patients Undergoing Elective Surgery
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Fresenius Kabi · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the therapeutic equivalence, based on pharmacodynamic parameters of Propofol 2% (20 mg/mL) MCT Fresenius and Diprivan® 20 mg/mL (AstraZeneca), administered by target controlled infusion (TCI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propofol | |
| DRUG | Diprivan |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-02-01
- First posted
- 2013-05-20
- Last updated
- 2014-02-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01856998. Inclusion in this directory is not an endorsement.